| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
UroGen Pharma Ltd.
13D/A
URGN · M96088105
|
1.9% |
6/9/2025
Event 6/5/2025
|
||||
| Monograph Capital Partners I, L.P. | 1.8% | |||||
| Monograph Capital Partners I GenPar, LP | 1.8% | |||||
| Monograph Capital Holdings Advisors, LLC | 1.8% | |||||
| Fred Cohen | 1.9% | |||||
| Charles Conn | 1.8% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.